Invention Grant
- Patent Title: ERK inhibitors
-
Application No.: US15529641Application Date: 2015-12-15
-
Publication No.: US09879029B2Publication Date: 2018-01-30
- Inventor: Guillermo S. Cortez , Sajan Joseph , Johnathan Alexander McLean , William Thomas McMillen , Michael John Rodriguez , Gaiying Zhao
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Tina M. Tucker; Dannica Hostettler
- International Application: PCT/US2015/065672 WO 20151215
- International Announcement: WO2016/106009 WO 20160630
- Main IPC: C07D495/04
- IPC: C07D495/04 ; C07B59/00
Abstract:
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
Public/Granted literature
- US20170267691A1 ERK INHIBITORS Public/Granted day:2017-09-21
Information query
